Sintilimab: First Global Approval-Reference-Cited by-同舟云学术

Sintilimab: First Global Approval

Published:2019-02 Issue:3 Volume:79 Page:341-346
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Hoy Sheridan M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-019-1066-z/fulltext.html

Reference14 articles.

1. Merryman RW, Armand P, Wright KT, et al. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1(26):2643–54.

2. Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.

3. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704–15.

4. Innovent Biologics. China’s NMPA approves Innovent’s anti-PD-1 antibody Tyvyt® (sintilimab injection) for Hodgkin’s lymphoma [media release]. 26 Dec 2018. http://innoventbio.com/en/#/news/123 .

5. Innovent Biologics. Tyvyt® (sintilimab): Chinese prescribing information. Suzhou: Innovent Biologics; 2019.

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment;Cancer Medicine;2024-01-12

2. Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review;Frontiers in Pharmacology;2023-12-12

3. Evaluation of Chelator-to-Antibody Ratio on Development of 89Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor;International Journal of Molecular Sciences;2023-12-05

4. Sintilimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel regimen as neoadjuvant therapy for resectable gastric cancer and biomarker exploration;Future Oncology;2023-11-22

5. Efficacy and safety of sintilimab combined with apatinib as third-line or above therapy for patients with advanced or metastatic gastric cancer;Anti-Cancer Drugs;2023-11-13